Brokers Issue Forecasts for IDYA FY2029 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Analysts at Wedbush issued their FY2029 EPS estimates for IDEAYA Biosciences in a research report issued to clients and investors on Thursday, February 13th. Wedbush analyst R. Driscoll anticipates that the company will post earnings per share of $1.20 for the year. Wedbush has a “Outperform” rating and a $52.00 price objective on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million.

Several other research analysts have also recently issued reports on IDYA. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Leerink Partnrs cut shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Stephens restated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday. UBS Group started coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $21.00 on Monday. IDEAYA Biosciences has a one year low of $20.63 and a one year high of $47.74. The stock has a market capitalization of $1.82 billion, a P/E ratio of -9.01 and a beta of 0.82. The firm’s 50 day simple moving average is $24.36 and its two-hundred day simple moving average is $29.88.

Institutional Investors Weigh In On IDEAYA Biosciences

Large investors have recently bought and sold shares of the business. Allworth Financial LP increased its holdings in IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after buying an additional 800 shares in the last quarter. Covestor Ltd increased its holdings in IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock worth $29,000 after buying an additional 922 shares in the last quarter. R Squared Ltd bought a new stake in IDEAYA Biosciences in the 4th quarter worth about $35,000. US Bancorp DE increased its holdings in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after buying an additional 689 shares in the last quarter. Finally, KBC Group NV increased its holdings in IDEAYA Biosciences by 29.1% in the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock worth $72,000 after buying an additional 513 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.